Enalapril (Enacard) for Dogs & Cats: ACE Inhibitor, Kidney Monitoring & 2,063 FDA Reports
A complete guide to enalapril for dogs and cats, covering its use as an ACE inhibitor, essential kidney and electrolyte monitoring, and an analysis of 2,063 FDA adverse event reports.
Enalapril is a widely used Angiotensin-Converting Enzyme (ACE) inhibitor in veterinary medicine. Prescribed primarily for congestive heart failure, systemic hypertension, and protein-losing kidney diseases in both dogs and cats, enalapril plays a crucial role in dilating blood vessels and managing fluid balance.
However, because of how it alters blood flow within the kidneys, its use requires systematic monitoring of renal parameters and careful attention to potential drug-drug interactions.
This guide provides a detailed, label-first review of enalapril for dogs and cats. We examine its cardiovascular and renal mechanics, clarify monitoring protocols, compare it to alternative medications, resolve common clinical questions, and analyze 2,063 adverse event reports from the FDA Center for Veterinary Medicine (CVM) database.
Quick Answer: What Owners and Vet Teams Need to Know
Enalapril (brand name Enacard, also known by the human brand Vasotec) is an oral ACE inhibitor. It is FDA-approved for managing mild, moderate, or severe congestive heart failure (CHF) in dogs (typically dosed at 0.5 mg/kg once or twice daily) and is used extra-label in cats.
Because enalapril alters the filtration pressure inside the kidneys, veterinarians must perform blood chemistry rechecks (specifically measuring Blood Urea Nitrogen [BUN], creatinine, and potassium) 1 to 2 weeks after starting the drug or changing the dose, followed by routine checks every 3 months.
Enalapril is not the same as Vetmedin (pimobendan), which is an inodilator that increases heart contraction strength, though the two drugs are frequently combined. It must be used with caution alongside NSAIDs (like carprofen or meloxicam) because the combination significantly increases the risk of acute kidney injury.
What Enalapril Does — ACE Inhibition for Heart Failure, Blood Pressure, and Proteinuria
The Biology of ACE Inhibition
Enalapril is a prodrug, meaning it is biologically inactive when ingested. Following oral administration, it is absorbed and rapidly hydrolyzed in the liver to its active metabolite, enalaprilat. Enalaprilat is a competitive inhibitor of Angiotensin-Converting Enzyme (ACE).
In a healthy animal, ACE is responsible for converting Angiotensin I into Angiotensin II. Angiotensin II is a potent hormone that affects the body in several ways:
- Vasoconstriction: It directly constricts arterial blood vessels, raising systemic vascular resistance and blood pressure.
- Aldosterone Release: It stimulates the adrenal cortex to release aldosterone, a hormone that instructs the kidneys to retain sodium and water, increasing blood volume.
- Myocardial Remodeling: It promotes pathological thickening and scarring (hypertrophy and fibrosis) of the heart muscle over time.
By inhibiting ACE, enalapril blocks the production of Angiotensin II. This leads to arterial vasodilation (reducing systemic vascular resistance, or afterload), decreases aldosterone secretion (reducing fluid retention, or preload), and mitigates destructive cardiac remodeling. For a failing heart, this reduction in workload makes it easier to pump blood effectively to the rest of the body.
Approved Veterinary Indication: Canine Congestive Heart Failure
Enalapril maleate tablets were approved by the FDA under New Animal Drug Application (NADA) 141-015 (Enacard, sponsored by Boehringer Ingelheim, formerly Merial). The approved label indicates its use for the treatment of mild, moderate, or severe heart failure in dogs in combination with standard therapy (typically a diuretic like furosemide and, in modern protocols, pimobendan).
The veterinary labeling aligns with the modified New York Heart Association (NYHA) functional classification:
- Class II(a) (Mild): Dogs with heart disease who are asymptomatic at rest but show mild exercise intolerance or coughing during physical activity.
- Class III(b) (Moderate): Dogs with obvious clinical signs of heart failure at rest, including tachypnea, coughing, and marked exercise intolerance.
- Class IV(c) (Severe): Dogs in decompensated congestive heart failure, showing signs of severe respiratory distress (pulmonary edema or pleural effusion) even while inactive.
In landmark clinical trials — the COVE study (controlled clinical evaluation of enalapril in moderate-to-severe heart failure) and the LIVE study (Long-Term Investigation of Veterinary Enalapril, which examined survival in dogs with naturally acquired heart failure) — dogs with congestive heart failure secondary to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM) who received enalapril alongside furosemide showed improved clinical scores, reduced pulmonary congestion, and a survival benefit compared with conventional therapy alone.
Extra-Label Uses: Hypertension and Proteinuria (Kidney Disease)
Under the provisions of the Animal Medicinal Drug Use Clarification Act (AMDUCA), enalapril is frequently used extra-label in both dogs and cats for:
Systemic Hypertension (High Blood Pressure): By dilating peripheral blood vessels, enalapril helps lower systemic arterial pressure, protecting target organs (such as the brain, eyes, and kidneys) from hypertensive damage.
Protein-Losing Nephropathy (PLN) and Proteinuria: In dogs and cats with glomerular kidney disease, proteins leak from the blood into the urine. Inside the kidneys, blood enters the glomerulus via the afferent arteriole and exits via the efferent arteriole. Angiotensin II normally constricts the efferent arteriole, increasing the filtration pressure inside the glomerulus.
By blocking Angiotensin II, enalapril dilates the efferent arteriole. This reduces the backpressure within the glomerular capillaries, thereby decreasing the mechanical force driving proteins across the damaged glomerular barrier. This antiproteinuric effect helps slow the progression of chronic kidney disease.
Extra-Label Use in Feline Medicine
While not FDA-approved for cats, enalapril is used clinically to manage feline hypertension, chronic kidney disease (CKD) with proteinuria, and hypertrophic cardiomyopathy (HCM) where afterload reduction is indicated. However, because cats are highly sensitive to changes in renal perfusion, dosing must be carefully titrated, and monitoring must be stringent.
Why Kidney and Electrolyte Monitoring Matters (and the Renal Signals in FDA Data)
Pathophysiology of the Renin-Angiotensin-Aldosterone System (RAAS)
To understand why enalapril therapy presents a renal hazard, it is necessary to examine the Renin-Angiotensin-Aldosterone System (RAAS). In a dog or cat with heart disease or chronic kidney disease, cardiac output falls, leading to decreased renal perfusion. The kidneys interpret this drop in blood flow as systemic hypotension or volume depletion. In response, the juxtaglomerular cells in the kidneys secrete the enzyme renin.
Renin cleaves angiotensinogen (produced by the liver) into Angiotensin I. As Angiotensin I circulates through the vasculature, Angiotensin-Converting Enzyme (mainly in the pulmonary capillaries) converts it to Angiotensin II. While Angiotensin II serves an acute survival function by maintaining blood pressure, its chronic activation in heart failure is highly destructive:
- Systemic Vasoconstriction: Spikes the resistance against which the left ventricle must pump (afterload), accelerating myocardial fatigue.
- Aldosterone Synthesis: Aldosterone binds to receptors in the distal nephron, prompting sodium and water retention. This expansion of plasma volume increases blood return to the heart (preload), stretching the weakened cardiac chambers and leading to pulmonary congestion (fluid leakage).
- Myocardial and Vascular Fibrosis: Angiotensin II acts as a growth promoter, driving cellular hypertrophy and collagen deposition in the heart wall, which reduces ventricular elasticity.
Enalapril breaks this cycle by blocking the conversion to Angiotensin II. However, because RAAS was actively maintaining glomerular filtration pressure, blocking it can compromise renal filtration.
The Glomerular Filtration Tradeoff
While dilating the efferent arteriole is beneficial for reducing protein leakage, it presents a metabolic hazard. In patients with severe heart failure or dehydration, renal blood flow is already compromised. The kidneys rely on Angiotensin II-mediated constriction of the efferent arteriole to maintain an adequate Glomerular Filtration Rate (GFR).
When enalapril is administered, this compensatory constriction is removed. The efferent arteriole dilates, and pressure within the glomerulus drops. In some patients, this drop is severe enough to cause a rapid decline in GFR, leading to prerenal azotemia (a buildup of nitrogenous waste products in the blood).
Additionally, because enalapril reduces aldosterone levels, the kidneys excrete less potassium. This can lead to hyperkalemia (elevated blood potassium), which can cause life-threatening cardiac arrhythmias if left unmanaged.
Standard Veterinary Monitoring Protocol
To balance cardiovascular benefits against renal risks, veterinary consensus guidelines recommend a structured monitoring schedule:
- Baseline: Prior to starting enalapril, perform a complete blood chemistry panel (measuring BUN, creatinine, and electrolytes) and urinalysis (to check specific gravity and protein levels).
- Week 1 to 2 Recheck: 7 to 14 days after starting enalapril (or after any increase in dose), recheck BUN, creatinine, and electrolytes.
- Acceptable Change: A minor increase in creatinine (up to 30% from baseline) is common and generally acceptable, reflecting hemodynamic adjustment.
- Action Threshold: If creatinine rises by more than 30%, or if the animal becomes clinically lethargic or anorexic, the enalapril dose should be reduced or suspended, and fluid balance should be reassessed.
- Routine Maintenance: Recheck renal values and electrolytes every 3 months for stable cardiac or renal patients.
Clinical Management of Rising Renal Values
If a patient's chemistry panel reveals a rise in BUN or creatinine exceeding the 30% threshold, the veterinary team must implement a systematic intervention plan:
- Dehydration Screening: Assess the patient's hydration status via skin turgor, mucous membrane moisture, and packed cell volume (PCV)/total solids. If the patient is dehydrated, enalapril should be suspended temporarily, and hydration should be restored.
- Adjust Concurrent Diuretics: In many cardiac patients, azotemia is driven by aggressive diuretic therapy (furosemide) rather than enalapril itself. The diuretic dose should be titrated down to the lowest level that controls pulmonary congestion before discontinuing the ACE inhibitor.
- Evaluate Blood Pressure: Measure systemic arterial pressure. If the patient is hypotensive (systolic pressure <90-100 mmHg), enalapril should be reduced or held, as low systemic pressure compromises renal perfusion.
- Consider a Drug Holiday: A temporary cessation of enalapril (3-5 days) can allow glomerular pressures to normalize. Once renal parameters stabilize, the drug can be reintroduced at 50% of the previous dose.
The NSAID "Triple Whammy" Risk
Co-administering enalapril with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, such as carprofen, meloxicam, deracoxib, or firocoxib) represents a significant clinical risk.
- NSAIDs block prostaglandins, which normally dilate the afferent (incoming) arteriole to keep blood flowing into the kidney. Blocking them constricts the afferent arteriole, reducing incoming blood flow.
- ACE Inhibitors (Enalapril) dilate the efferent (outgoing) arteriole, dropping the filtration pressure inside the kidney.
- Diuretics (Furosemide) reduce overall blood volume.
When these three drugs are combined (the "triple whammy"), the kidneys experience a severe reduction in both incoming blood flow and internal filtration pressure. This can precipitate acute kidney injury (AKI). If an NSAID is necessary for an enalapril-treated patient, kidney values must be monitored closely, and the lowest effective NSAID dose should be used.
Enalapril vs Vetmedin (pimobendan) vs Benazepril and Telmisartan
Selecting the right cardiac or renal medication requires distinguishing between different drug classes and clearance pathways.
| Drug Name & Class | Primary Mechanism | Clearance Pathway | Main Indications | Clinical Distinction |
|---|---|---|---|---|
| Enalapril (ACE Inhibitor) | Blocks Angiotensin II production; vasodilates; reduces aldosterone. | Renal (excreted primarily by kidneys). | Heart failure (dogs), hypertension, proteinuria. | Workhorse ACE inhibitor; requires dose reduction in patients with kidney failure. |
| Vetmedin / Pimobendan (Inodilator) | Increases calcium sensitivity of cardiac muscle (contractility); dilates blood vessels via PDE3 inhibition. | Fecal (hepatic metabolism). | Mitral valve disease (Stage B2/C/D), dilated cardiomyopathy. | Not an ACE inhibitor. Directly strengthens heart contractions. (See our Vetmedin guide). |
| Benazepril (ACE Inhibitor) | Blocks Angiotensin II production; identical clinical effects to enalapril. | Biliary and Renal (dual clearance). | Congestive heart failure, chronic kidney disease. | Often preferred over enalapril in cats and dogs with significant kidney disease, as the liver compensates for reduced renal clearance. |
| Telmisartan (Angiotensin Receptor Blocker) | Blocks Angiotensin II Type 1 (AT1) receptors. | Fecal (biliary excretion). | Feline hypertension, protein-losing nephropathy. | Blocks Angiotensin II at the receptor level; excellent safety profile in cats. (See our telmisartan guide). |
| Furosemide (Loop Diuretic) | Inhibits sodium reabsorption in the Loop of Henle; increases urine output. | Renal | Congestion, pulmonary edema (fluid in lungs). | Diuretic to clear active fluid congestion; does not vasodilate or alter remodeling. (See our furosemide guide). |
Clinical Integration
Enalapril is rarely used alone in cardiology. In canine congestive heart failure secondary to MMVD, it is introduced alongside pimobendan and furosemide once clinical signs of congestion (Stage C) emerge.
While pimobendan is started early in Stage B2 (cardiomegaly without active failure) based on the EPIC trial, ACE inhibitors like enalapril are typically reserved for Stage C, where active congestion is present. For more details on these stages, see our heart-murmur staging guide and our congestive heart failure overview.
What Happens if You Stop Enalapril Suddenly, and Whether It Helps Coughing
The Danger of Abrupt Discontinuation
Owners should never stop administering enalapril abruptly. In a dog or cat with chronic heart failure or hypertension, the body has adapted to the presence of the drug. Stopping it suddenly can cause a rebound effect:
- An abrupt surge in Angiotensin II levels.
- Sudden, severe vasoconstriction (spiking blood pressure).
- A rapid increase in the heart’s workload (afterload).
- Acute sodium and water retention.
This sudden hemodynamic shift can destabilize a well-managed cardiac patient, potentially causing them to slide back into acute congestive heart failure (pulmonary edema) or experience hypertensive crises (such as retinal detachment or strokes in cats). If discontinuation is necessary (e.g., during acute renal failure), it should be done under direct veterinary supervision, often replacing the drug or tapering the dose while supporting blood pressure.
Does Enalapril Help Coughing?
A common area of confusion for owners is whether enalapril will stop a dog from coughing.
Coughing in dogs with mitral valve disease is generally caused by one of two mechanisms:
- Mechanical Compression: An enlarged left atrium (due to mitral regurgitation) physically presses upward against the left mainstem bronchus, triggering a mechanical tickle and chronic cough.
- Pulmonary Edema: Fluid leaking into the lung tissue due to elevated left-sided heart pressures.
Enalapril does not act as a cough suppressant. It does not soothe the airways or stop mechanical compression. While it helps reduce the pressures that drive pulmonary edema, the drug that actively clears fluid congestion and relieves a fluid-induced cough is furosemide (a diuretic).
If a dog on enalapril continues to cough, the owner should monitor the dog's Resting Respiratory Rate (RRR) at home (which should consistently remain under 30 breaths per minute while sleeping) and consult their veterinarian, rather than increasing the enalapril dose.
What the 2,063 FDA Adverse-Event Reports Naming Enalapril Show
To analyze the safety profile of enalapril in the real world, we evaluated the adverse-event dataset maintained by the FDA Center for Veterinary Medicine (CVM), filtering for unique records naming enalapril (extract dated July 5, 2026, run 20260705_full).
Pharmacovigilance and Spontaneous Reporting Limits
Spontaneous reporting databases are valuable for identifying safety trends, but they have limitations. A report of an adverse event does not prove that the drug was the cause. Reported events can be influenced by underlying diseases, age, and concomitant medications. Spontaneous reports are also subject to under-reporting.
Dataset Overview
- Total Unique Reports: 2,063
- Species Split:
- Dog (Canine): 1,631 reports (79.0%)
- Cat (Feline): 104 reports (5.0%)
- Unknown Species: 321 reports (15.6%)
- Human: 6 reports (0.3%)
- Severity Profile:
- Serious Adverse Events: 780 reports (37.8%)
- Non-Serious Events: 764 reports (37.0%)
- Unknown Severity: 519 reports (25.2%)
The Confound of Polypharmacy
The dataset confirms that enalapril is almost always prescribed as part of a multi-drug regimen:
- Monotherapy Reports (n_drugs = 1): 394 reports (19.1%)
- Polypharmacy Reports (n_drugs >= 2): 1,669 reports (80.9%)
- Common Co-administered Drugs: Furosemide, pimobendan, spironolactone, and NSAIDs.
Because four-fifths of the reports involve multiple medications, many of the clinical signs reported (such as lethargy or wobbly gait) may be due to the combination of drugs, changes in fluid balance, or the progression of heart failure, rather than enalapril alone.
Top Reported Reaction Terms
The table below lists the top VeDDRA reaction terms documented in the enalapril reports.
| VeDDRA Reaction Term | Count of Reports | Clinical Context and Interpretation |
|---|---|---|
| Vomiting | 257 | Standard gastrointestinal reaction; can occur with initial dosing. |
| Lethargy | 220 | Generalized weakness. Can reflect a drop in blood pressure (hypotension) or systemic dehydration. |
| Diarrhoea | 217 | Gastrointestinal irritation. |
| Death by euthanasia | 175 | Reflects the end-stage nature of the cardiac and renal patient population, rather than direct drug-induced toxicity. |
| Elevated BUN | 137 | The primary renal safety signal. Quantifies the importance of the recommended 1 to 2-week chemistry recheck. |
| Anorexia | 136 | Appetite loss. Can be a sign of worsening kidney function (uremia) or hypotension. |
| Containers, Damaged | 133 | Product quality artifact. This represents physical damage to packaging or bottle integrity reported to the FDA, not a biological adverse effect on patients. |
| Seizure - NOS | 124 | Often reported in geriatric dogs; likely reflects underlying central nervous system pathology or severe metabolic derangement rather than direct enalapril toxicity. |
| Death | 116 | Reflects the high mortality of end-stage congestive heart failure. |
| Weight loss | 108 | Chronic indicator of systemic disease, heart failure cachexia, or chronic kidney disease. |
| Elevated ALT | 98 | A liver enzyme elevation signal; requires monitoring in multi-drug regimens. |
| Decreased appetite | 97 | Mild anorexia; commonly noted during drug introduction. |
| Elevated creatinine | 92 | Renal safety signal. Pairs with elevated BUN to indicate a reduction in glomerular filtration rate. |
| Not eating | 91 | Overlaps with anorexia; frequently associated with advanced heart failure. |
| Ataxia | 89 | Wobbly gait. Can indicate weakness, severe hypotension (blood pressure dropping too low), or concurrent spinal/joint disease. |
Documented Outcomes in the Dataset
The outcomes recorded in these reports were:
- Recovered/Normal: 404
- Ongoing (Unresolved): 395
- Euthanized: 163
- Died: 133
- Recovered with Sequela: 37
Note on Death and Euthanasia: In 296 reports, the animal died or was euthanized. This high percentage (14.3%) reflects the fact that enalapril is typically prescribed to geriatric dogs and cats with advanced, progressive, and life-limiting diseases (congestive heart failure and chronic renal failure). It does not indicate that the drug itself is inherently lethal.
FAQs: Common Owner and Practitioner Questions
Is enalapril the same as Vetmedin?
No. Enalapril is an ACE inhibitor (a vasodilator that dilates blood vessels to lower blood pressure and reduce the heart's workload). Vetmedin (pimobendan) is an inodilator, which works by increasing the calcium sensitivity of the heart muscle (strengthening contractions) and causing vasodilation. They belong to different drug classes and are frequently prescribed together to manage congestive heart failure.
Does enalapril help with coughing in dogs?
Not directly. Enalapril is not a cough suppressant. If a dog’s cough is caused by fluid in the lungs (pulmonary edema), a diuretic like furosemide is the primary drug needed to clear it. If the cough is mechanical (an enlarged heart pressing on the airway), dilating blood vessels with enalapril and pimobendan may help reduce heart size over several months, but it will not provide rapid cough relief.
What happens if I stop giving my dog enalapril?
You should not stop enalapril suddenly. Doing so can cause a rebound effect, resulting in sudden vasoconstriction and fluid retention. This sudden increase in blood pressure and heart workload can cause a stable cardiac patient to decompensate into acute heart failure. Always consult your veterinarian before altering or stopping any cardiac medication.
Bottom Line: Practical Decision Support
Enalapril is a foundational medication for managing cardiovascular and renal disease in dogs and cats. Its success relies on a balanced approach to treatment:
- Mandatory Bloodwork Rechecks: Always perform a chemistry panel 1 to 2 weeks after starting the drug or changing the dose to check BUN, creatinine, and potassium.
- Avoid NSAID Combinations: Exercise caution when prescribing NSAIDs to a patient taking enalapril to protect renal function.
- Differentiate Roles: Remember that enalapril manages vascular resistance and remodeling; it does not replace diuretics for fluid clearance or inodilators for contraction strength.
- Do Not Stop Abruptly: Ensure continuous administration to avoid rebound hypertension and cardiac strain.
Sources
- Drugs.com / NOAH Compendium, ENACARD Tablets for Dogs (NADA 141-015 Product Label): https://www.drugs.com/vet/enacard-tablets-for-dogs.html
- Merck Veterinary Manual, Angiotensin-Converting Enzyme Inhibitors for Use in Animals: https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-converting-enzyme-inhibitors-for-use-in-animals
- VCA Animal Hospitals, Enalapril Monitoring Guidelines: https://vcahospitals.com/know-your-pet/enalapril
- DVM360, A Practical Guide to Antiproteinuric Drugs in Dogs: https://www.dvm360.com/view/practical-guide-antiproteinuric-drugs-dogs
- Veterinary Partner (VIN), Enalapril Maleate (Enacard, Vasotec): https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102894&id=4951417
- Journal of Veterinary Internal Medicine, PMID 8523321 (COVE Study Group, 1995 — Controlled clinical evaluation of enalapril in dogs with heart failure): https://pubmed.ncbi.nlm.nih.gov/8523321/
- FDA CVM, Animal Adverse Event Reports Database, July 5, 2026 public extract: https://api.fda.gov/animalandveterinary/event.json
